The treatment landscape for acute myeloid leukemia (AML) is rapidly evolving, leaving clinicians with the task of creating individualized treatment plans incorporating molecular and genetic testing results. Tune in to hear expert faculty as they examine the latest clinical evidence for novel therapies and share strategies for interpreting and integrating molecular testing results into guideline-aligned treatment plans for AML. Featuring expert strategies for recognition, mitigation, and management of AML-targeted therapy-related adverse events, don’t miss this opportunity to learn best practices on optimizing AML care in federal and public health settings.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/precision-targeting-acute-myeloid-leukemia-optimizing-disease-informed-patient
- Start Date: 2024-11-01 05:00:00
- End Date: 2024-11-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 6250.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 9375.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 7437.5 - Is Kind Support: False Source: Sobi - Amount: 6250.0 - Is Kind Support: False Source: Taiho Pharmaceutical - Amount: 12437.5 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest